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During miRNA biogenesis, the microprocessor com-
plex (MC), which is composed minimally of Drosha,
an RNase III enzyme, and DGCR8, a double-stranded
RNA-binding protein, cleaves the primary miRNA
(pri-miRNA) in order to release the pre-miRNA
stem-loop structure. Using phosphoproteomics, we
mapped 23 phosphorylation sites on full-length
human DGCR8 expressed in insect or mammalian
cells. DGCR8 can be phosphorylated by mitogenic
ERK/MAPK, indicating that DGCR8 phosphorylation
may respond to and integrate extracellular cues.
The expression of phosphomimetic DGCR8 or inhibi-
tion of phosphatases increased the cellular levels of
DGCR8 and Drosha proteins. Increased levels
of phosphomimetic DGCR8 were not due to
higher mRNA levels, altered DGCR8 localization, or
DGCR8’s ability to self-associate, but rather to an
increase in protein stability. MCs incorporating phos-
phomutant or phosphomimetic DGCR8 were not
altered in specific processing activity. However,
HeLa cells expressing phosphomimetic DGCR8 ex-
hibited a progrowth miRNA expression profile and
increased proliferation and scratch closure rates
relative to cells expressing phosphomutant DGCR8.INTRODUCTION
miRNAs are 22 nt long and posttranscriptionally regulate their
target mRNAs through degradation and translational repression
(Guo et al., 2010). They are involved in a diverse array of biolog-
ical processes ranging from cell growth, survival, and differenti-
ation to disease states such as cancer. miRNA genes are
typically transcribed by RNA polymerase II into long, capped,
and polyadenylated primary transcripts (pri-miRNAs), which
follow a two-step processing pathway to yield a mature miRNA.
The nuclear microprocessor complex (MC), which is composed1070 Cell Reports 5, 1070–1081, November 27, 2013 ª2013 The Autof the ribonuclease (RNase) III enzyme Drosha and its essential
cofactor DGCR8, excises a 70 nt stem-loop structure (the
pre-miRNA) with a 50 phosphate and a 2 nt 30 overhang (Denli
et al., 2004; Gregory et al., 2004; Han et al., 2004; Landthaler
et al., 2004). This step is critical for proper miRNA biogenesis
because the Drosha cleavage site defines the sequence of the
mature miRNA by generating one end of the 22 nt mature
miRNA. The resulting pre-miRNA is then transported by the
Exportin-5/Ran-GTP complex to the cytoplasm, where it is
further processed by the RNase III enzyme Dicer. Dicer, together
with a double-stranded RNA binding domain (dsRBD)-contain-
ing protein, TRBP2, cleaves the upper hairpin stem, generating
2 nt 30 overhangs on the 22 nt dsRNA product (Chendrimada
et al., 2005; Haase et al., 2005). One strand is then incorporated
into an RNA-induced silencing complex (RISC), whose main
component is an Argonaute family protein. This complex targets
mRNAs via basepairing between the miRNA and mRNA,
resulting in the regulation of protein expression.
Several proteins involved in miRNA processing are regulated
by posttranslational modifications (PTMs). TRBP2 stability
is increased upon phosphorylation by extracellular signal-
regulated kinases (ERKs), leading to increased Dicer and pro-
growth miRNA levels (Paroo et al., 2009). Upon cell-cycle
reentry, Exportin 5 expression is posttranscriptionally induced
in a phosphoinositide 3-kinase (PI3K) pathway-dependent
process (Iwasaki et al., 2013). Phosphorylation of Drosha by
glycogen synthase kinase-3b (GSK3b) is required for proper
Drosha localization to the nucleus (Tang et al., 2010, 2011),
and acetylation of Drosha inhibits its degradation (Tang et al.,
2013). The ability of DGCR8 to bind RNA has been reported to
bemodulated by acetylation of lysine residues within its dsRBDs
(Wada et al., 2012). Although ten phosphorylation sites in
DGCR8 have been mapped in high-throughput tandem mass
spectrometry (MS/MS) studies of total mammalian cell lysates
(Dephoure et al., 2008; Olsen et al., 2006), the roles of these
phosphorylations remain elusive.
DGCR8 function is clearly important, as it is essential for
viability in mice and DGCR8-knockout embryonic stem cells
showaproliferation defect (Wanget al., 2007). DGCR8deficiency
in the brain has also been suggested to cause behavioral and
neuronal defects associatedwith the 22q11.2 deletion syndromehors
known as DiGeorge syndrome (Schofield et al., 2011; Stark et al.,
2008). As an essential component of theMC,DGCR8 (1) localizes
to thenucleus, (2) associateswithDroshaandRNA, and (3) allows
Drosha’s RNase III domains to access the RNA substrate. The
stoichiometry of DGCR8 and Drosha within the MC remains
unclear (Gregory et al., 2004; Han et al., 2004); however, purified
DGCR8 has been shown to form a dimer (Barr et al., 2011; Faller
et al., 2007; Senturia et al., 2012). It is therefore possible that
DGCR8’s subcellular localization and/or ability to associate
with cofactors (RNA, Drosha, or itself) could be affected by
phosphorylation. Likewise, the altered phosphorylation status
of DGCR8 in conditions of uncontrolled cell signaling, as in
cancer cells, could contribute to the disease phenotype.
In this study, we confirm that humanDGCR8 is phosphorylated
in metazoan cells. Using peptide fractionation and phosphopep-
tide enrichment strategies, we mapped 23 phosphosites on
DGCR8, the 10 previously identified sites (Dephoure et al.,
2008; Olsen et al., 2006), plus an additional 13. At least some
of these sites are targeted by ERK, indicating an important
regulatory function. By mutating these amino acids to either pre-
vent ormimic phosphorylation,we found thatmultisite phosphor-
ylation stabilized the DGCR8 protein. Expression of the mimetic
DGCR8 construct showed increased protein levels relative to a
wild-type (WT) DGCR8 construct and led to an altered progrowth
miRNA expression profile, and enhanced cell proliferation. These
data implicate DGCR8 as a critical link between extracellular pro-
liferative cues and reprogramming of the cellular miRNA profile.
RESULTS
DGCR8 Is Multiply Phosphorylated
To verify that DGCR8 is phosphorylated in metazoan cells, we
transiently expressed human N-terminally FLAG-hemagglutinin
(HA)-tagged DGCR8 (FH-DGCR8) and Myc-Drosha in either
human embryonic kidney (HEK) 293T or HeLa cells metabolically
labeled with radioactive orthophosphate. DGCR8 immunopre-
cipitated from both cell lines showed 32P incorporation (Figures
1A and 1B). To create a comprehensive phosphorylation profile,
we expressed tagged human DGCR8 and immunopurified it
from baculovirus-infected Hi-5 insect cells or transiently trans-
fected HEK293 cells. Then, we coupled peptide fractionation
protocols and phosphopeptide enrichment strategies with
high-resolution MS/MS and MaxQuant software (Cox et al.,
2011) for data analysis (Figure 1C). We obtained 73% total amino
acid sequence coverage of DGCR8 from the baculovirus-in-
fected insect cell culture (Figure S1), which allowed us to confirm
nine of the ten phosphosites reported from high-throughput
studies (Dephoure et al., 2008; Olsen et al., 2006) and map ten
additional phosphosites (Table 1). In two independent ex-
periments analyzing phosphosites on DGCR8 expressed in
HEK293 cells, we obtained 53% and 60% sequence coverage,
respectively (Figure S1). All ten known sites and four of the ten
newly identified sites were confirmed, and three additional sites
were mapped (Table 1). All of the identified sites exhibited high
MaxQuant scores (>60) and low posterior error probability
scores (<0.1) in at least one experiment, and most (19 of 23)
were found in multiple peptides (Table 1). Sites that had scores
lower than 60 or had not previously been identified in high-Cell Rethroughput studies were not considered further (Table S1).
Representative spectra of phosphopeptides for each site are
shown in Figure 1D and Data S1. Several examples of peptides
phosphorylated at multiple sites were observed (Figure 1D lower
spectra; Data S1), suggesting that multisite phosphorylation
might be important for DGCR8 function.
Overall, we detected a total of 23 phosphorylation sites in
DGCR8 (Figure 1E) with high statistical confidence. Most of
these phospho-acceptor sites are conserved over a number of
species (data not shown). All 23 sites occur in the N terminus
of DGCR8, outside regions for which three-dimensional struc-
tures have been determined (Senturia et al., 2012; Sohn et al.,
2007; Wostenberg et al., 2010). Consistent with global analyses
of the structural context of phosphorylation sites (Holt et al.,
2009), a secondary structure prediction of DGCR8 suggests
that 21 of the 23 sites reside in loops that should be accessible
to kinases and may represent regions of protein-protein interac-
tions (data not shown).
To ensure that we mapped all relevant phosphosites in
DGCR8 under our growth conditions, we mutated each of the
23 phosphosites in the FH-DGCR8 construct to either prevent
or mimic phosphorylation (hereafter referred to as Mut23 and
Mim23, respectively; see Table S2 for details). Immunoprecipita-
tion of Mut23 from cells metabolically labeled with 32P-ortho-
phosphate showed no 32P signal, whereas Mim23 showed less
signal than theWT, despite higher total protein levels (Figure 1F).
The remaining 32P signal for Mim23 may be due to phosphoryla-
tion at phosphosites identified with lower statistical confidence
(Table S1). The higher DGCR8 protein levels resulting from
expression of the Mim23 construct suggested that phosphoryla-
tion might stabilize the exogenous DGCR8 protein.
DGCR8 Is Phosphorylated by Mitogenic MAPKs
Methods for predicting kinase-substrate pairs suggested that
many cellular kinases could be involved in phosphorylating
DGCR8 (Table S3). However, from a panel of phospho-(Ser/
Thr) kinase substrate antibodies (MAPK/CDK, AKT, PKA, ATM/
ATR, and PKC), DGCR8 immunopurified from insect cells was
recognized by the anti-MAPK/CDK substrate antibody (Fig-
ure 2A). Since DGCR8 possesses MAPK docking motifs that
match both of the recently structurally defined motifs that are
specific for JNK and ERK/p38 kinases (Garai et al., 2012; Fig-
ure S2A), we probed immunoblots of anti-FLAG-immunoprecip-
itatedMCs fromHEK 293T cell extracts for the presence of these
kinases (Figure 2B). JNK1 and JNK2 and ERK1 and ERK2, but
not p38, were specifically coimmunoprecipitated, but not from
the negative control extract where DGCR8 with an alternate
tag (SNAP) was expressed. Protein phosphatase 2A subunit A
was also coimmunoprecipitated with MCs (Figure 2B), pointing
to an equilibrium between phosphorylation and dephosphoryla-
tion that might be regulated by cellular conditions.
To confirm that JNK and ERK can phosphorylate DGCR8, we
performed in vitro kinase assays with bacterially expressed
DGCR8 and immunopurified kinases. A constitutively active
form of JNK (FLAG-MKK7B2-JNK1a1 WT: FLAG-JNK1a1 fused
to its upstream kinase MKK7; Zheng et al., 1999) or the signifi-
cantly less active WT JNK1a1, expressed and immunopurified
from HEK 293T cells (Figure S2B, left) was specifically able toports 5, 1070–1081, November 27, 2013 ª2013 The Authors 1071
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Figure 1. DGCR8 Is Multiply Phosphorylated
(A and B) DGCR8 expressed in mammalian cell lines shows 32P incorporation due to phosphorylation. HeLa (A) and HEK 293T (B) cells were transiently
transfected with vectors expressing FH-DGCR8, Myc-Drosha, and GFP (as a transfection control). Cells were metabolically labeled with 32PO4, and anti-FLAG
immunoprecipitation was used to isolate MCs. Immunoblots, 32P, and Coomassie-stained gel images are shown. Lanes that were not run next to each other were
moved together. In (A), immunopurified MCs were subjected to phosphatase treatment either alone or in the presence of phosphatase inhibitors.
(C) Purification and enrichment scheme for isolating DGCR8 phosphopeptides.
(D) Representative fragmentation spectra of two identified phosphopeptides. Each spectrum shows relative intensity measurements of mass-to-charge ratios
(m/z) after assigning the most abundant ion 100%. The ‘‘b’’ and ‘‘y’’ fragmentation ions are indicated in red along the peptide sequence assigned to the spectrum.
Phosphorylated residues are indicated with a ‘‘p.’’ Spectra are labeled as follows: precursor ion (unfragmented peptide), H20 (water loss), NH3 (ammonium
loss), * (oxidation), and 2+ or 3+ (charge). Red lines indicate signals corresponding to assigned peptide fragments, and black lines are unassigned. Each
fragmentation spectrum explains the assigned sequence.
(E) Schematic diagram of the domain structure of DGCR8 with the 23 mapped phosphosites indicated. Previously identified sites are shown in red (Olsen et al.,
2006) and blue (Dephoure et al., 2008). Regions that are important for various functions of DGCR8 are indicated (Faller et al., 2007; Yeom et al., 2006).
(F) HEK 293T cells were transiently transfected with vectors expressing GFP (as a transfection and RNA loading control), Myc-Drosha, and either an empty vector
orWT-FH-DGCR8, Mut23-FH-DGCR8, or Mim23-FH-DGCR8. Cells weremetabolically labeled with 32PO4 andMCs isolated via anti-FLAG immunoprecipitation.
Immunoblots (bottom) and 32P (top) images are shown. See also Figure S1, Data S1, and Table S2.phosphorylate DGCR8 in vitro (Figure S2B, right). Activated ERK
was obtained by coexpressing and immunoprecipitating HA-
ERK with a constitutively active (R4F) version of its upstream1072 Cell Reports 5, 1070–1081, November 27, 2013 ª2013 The Autkinase MKK1, whereas HA-ERK expressed with a kinase-dead
(K97M) version of MKK1 or without any MKK1 yielded inactive
ERK (Figure S2C). Only activated ERKwas able to phosphorylatehors
Table 1. Phosphosites Mapped on His-DGCR8 Isolated from HEK293 or Hi-5 Insect Cells
aa Sites
HEK293 Cells Experiment 1 HEK293 Cells Experiment 2 Hi-5 Insect Cells
Coverage 52.9%
No. of Peptides
Phosphorylated Coverage 60.0%
No. of Peptides
Phosphorylated Coverage 73.5%
No. of Peptides
Phosphorylated
PEP Score Total PEP Score Total PEP Score Total
S35 1.34 3 1019 113.1 2/2 NA NA 0/0 8.59 3 1014 158.2 7/8
T42 NA NA 0/2 NA NA 0/0 8.59 3 1014 158.2 1/8
S59 NA NA 0/2 NA NA 0/0 9.01 3 102 83.4 1/8
S92 NA NA 0/6 3.32 3 102 56.4 1/45 8.60 3 102 72.2 1/9
S95 NA NA 0/6 4.58 3 1071 101.4 3/45 8.60 3 102 72.2 1/9
S109 1.92 3 102 40.7 8/22 4.32 3 102 40.8 7/26 3.88 3 101 31.4 2/7
S123 NA NA 0/0 1.21 3 103 72.1 3/51 NA NA 0/2
T125 NA NA 0/0 1.21 3 103 72.1 1/51 NA NA 0/2
S153 NA NA 0/0 NA NA 0/1 6.91 3 105 112.1 7/10
S156 NA NA 0/0 NA NA 0/1 6.91 3 105 112.1 2/10
Y267 2.40 3 1016 117.9 2/28 NA NA 0/10 3.14 3 1015 164.5 1/35
S271 2.40 3 1016 117.9 23/28 1.88 3 1085 247.2 8/10 3.14 3 1015 164.5 22/35
S275 1.32 3 105 79.1 17/28 1.88 3 1085 247.2 7/10 1.03 3 1022 183.8 19/35
T279 2.40 3 1016 117.9 2/28 NA NA 0/10 NA NA 0/35
S280 2.40 3 1016 117.9 1/28 NA NA 0/10 NA NA 0/35
T371 3.89 3 1033 134.4 2/37 2.89 3 1043 204.0 1/30 1.89 3 105 122.5 7/28
S373 3.89 3 1033 134.4 3/37 2.89 3 1043 204.0 3/30 1.89 3 105 122.5 4/28
S377 7.67 3 1054 152.8 21/37 1.05 3 1015 147.0 16/30 2.70 3 1015 169.0 22/28
S383 3.89 3 1033 134.4 1/37 1.05 3 1015 147.0 1/30 2.70 3 1015 169.0 1/28
S385 NA NA 0/19 NA NA 0/30 9.12 3 104 101.5 4/23
S397 1.75 3 101 63.3 3/19 NA NA 0/4 9.12 3 104 101.5 1/23
S434 NA NA 0/5 7.54 3 102 37.075 1/72 7.27 3 103 92.5 4/14
S493 5.16 3 1021 123.1 1/59 3.49 3 102 51.5 2/59 1.51 3 103 102.7 1/15
The amino acid number of each newly mapped phosphosite or previously identified phosphosite (italic [Dephoure et al., 2008] or bold [Olsen et al.,
2006]) is shown with the values for the posterior error probability (PEP), andMaxQuant score. Also shown are the fractions of phosphorylated peptides
(Total). See also Table S1.bacterially expressed DGCR8, yielding 32P-phosphorylated
bands that increased in intensity with increasing kinase (Fig-
ure 2C, top) or substrate (Figure 2C, bottom) levels. To determine
whether these kinases also phosphorylate DGCR8 in vivo, we
serum starved a HeLa cell line that we developed to stably over-
express FLAG-DGCR8 (F-DGCR8) from a chromosomal locus
(Flp-In cells; see the Supplemental Experimental Procedures)
overnight, added either DMSO, the MKK1 inhibitor UO126, or
the JNK inhibitor SP600125 prior to serum, and metabolically
labeled the cellswith 32P-orthophosphate.Whenwe immunopre-
cipitated DGCR8 and assessed the amount of 32P incorporation,
we found that U0126 reduced the levels of activated phospho-
ERK induced by serum addition and also showed significantly
less 32P incorporation into DGCR8 (Figure 2D) relative to the
DMSO control. These results indicate that DGCR8 is phosphory-
lated by ERKs in response to serum addition. The JNK inhibitor
SP600125 increased the 32P-DGCR8 levels (Figure 2D) relative
to cells treated with the DMSO control, possibly due to the
compensatory overactivation of ERK kinases that is often
observed during the inhibition of other MAPKs (Ohashi et al.,
2004; Paroo et al., 2009). However, we were unable to detect
JNK activation in response to serum addition (Figure S2D) andCell Reit remains to be determined whether DGCR8 is phosphorylated
by JNK in response to other stimuli, such as UV stress.
DGCR8 Phosphorylation Increases Microprocessor
Levels by Increasing DGCR8 Protein Stability
To further test the correlation between DGCR8 phosphorylation
and the observed DGCR8 protein levels (Figure 1F), we treated
HeLa cells transfected with our FH-DGCR8 constructs with caly-
culin A, a serine/threonine phosphatase inhibitor. Upon calyculin
A treatment, we observed2.3-fold and 1.7-fold higher levels of
WT-FH-DGCR8 andMyc-Drosha (Figure 3A, Cal versus D lanes),
respectively, as would be expected if indeed increased phos-
phorylation stabilizes DGCR8 (DGCR8 and Drosha levels are
known to correlate since DGCR8 stabilizes Drosha protein;
Han et al., 2009; Triboulet et al., 2009). Mut23 yielded DGCR8
levels similar to those observed for theWT (relative to the glycer-
aldehyde 3-phosphate dehydrogenase [GAPDH] loading con-
trol) in untreated cells, and Mim23 showed similar levels relative
to WT in calyculin A-treated cells. Neither of the mutated con-
structs exhibited increased protein levels upon calyculin A treat-
ment (Figure 3A). This result reconfirms that we have identified
most, if not all, of the relevant phosphosites responsible forports 5, 1070–1081, November 27, 2013 ª2013 The Authors 1073
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Figure 2. DGCR8 Is Targeted by ERK/
MAPKs In Vivo
(A) Recombinant DGCR8 purified from baculovi-
rus-infected insect cells, but not from E. coli, is
recognized by an anti-Phospho-Thr CDK/MAPK
substrate antibody. Left: Coomassie-stained
SDS-PAGE of affinity-purified proteins. Right:
immunoblot of the same affinity-purified pro-
tein samples (either phosphatase treated or
untreated) probed with an anti-CDK/MAPK sub-
strate antibody.
(B) Selected MAPKs can be immunopurified
with MCs. HEK 293T cells were transiently trans-
fected with vectors expressing GFP, Myc-Drosha,
and either an empty vector or WT-FH-DGCR8,
Mut23-FH-DGCR8, Mim23-FH-DGCR8, or WT-
SNAP-DGCR8. Immunoblots of anti-FLAG immu-
noprecipitated MCs were probed for ERK, p38, or
JNK MAPKs, as well as for PP2A A and GAPDH.
(C) DGCR8 can be phosphorylated by ERKs
in vitro. 32P-exposed gel images of ERK in vitro
kinase assays. HA-ERK was immunoprecipitated
from HEK 293T cells that had been transfected
with either GFP alone (as a negative control []) or
HA-ERK together with its upstream kinase MKK1-
K97M (kinase dead), MKK1-R4F (constitutively
active), or GFP. Immunoprecipitated ERK was
incubated with bacterially expressed DGCR8. The
top gel shows constant DGCR8 substrate levels
(7.5 ml) with varying kinase levels (2, 5, or 10 ml
immunoprecipitate), and the bottom gel shows
increasing substrate levels (0, 7.5, 15 ml) with
constant immunoprecipitated ERK levels (7.5 ml).
The final lane of each gel shows the control
immunoprecipitate incubated with DGCR8 using
the highest levels of control immunoprecipitate
(top gel) or DGCR8 (bottom gel).
(D) ERKs can phosphorylate DGCR8 in vivo. Strain 1 HeLa Flp-In cells stably expressing WT-F-DGCR8 or an empty vector were serum starved overnight and
treated for 2 hr with DMSO control, U0126 (MEK1/2 inhibitor), or SP600125 (JNK inhibitor). Cells were then metabolically labeled with 32PO4 upon serum addition
for 4 hr. Total cell lysates (input) were probed for p-ERK in the upper immunoblots. Anti-FLAG immunoprecipitates were probed for DGCR8 and the 32P signal was
assessed in the lower immunoblots. Numbers indicate the amount of 32P normalized to the DGCR8 signal.
See also Table S3 and Figure S2.increasing DGCR8 protein levels. More importantly, we conclude
that increased phosphorylation of DGCR8 leads to increased
protein levels.
To corroborate the effect of multisite phosphorylation
on DGCR8 protein levels, we expressed in HEK 293T cells con-
structs containing subsets of residues mutated to either prevent
(Mut23 andMut14 have 23 and 14 sites mutated, respectively) or
mimic (Mim11 andMim23 have 11 and 23 sitesmutated, respec-
tively; Table S2) phosphorylation. We examined the protein and
mRNA levels for these constructs via immunoblots of cellular
lysates and northern blot analyses of total RNA prepared from
these cells, respectively (Figure 3B, left, with quantitations on
the right). Increased DGCR8 protein levels were observed
as the number of residues available for phosphorylation or
mimicking phosphorylation increased, whereas DGCR8 mRNA
levels remained constant for all constructs. Additional mutants
with single sites or clusters of sites mutated to prevent or mimic
phosphorylation were examined, but they exhibited no obvious
phenotypes (data not shown). Thus, the multisite phosphoryla-
tion of DGCR8 appears to regulate DGCR8 stability in a graded1074 Cell Reports 5, 1070–1081, November 27, 2013 ª2013 The Autfashion, rather than phosphorylation exceeding a threshold
beyond which DGCR8 stability is changed in a sharp, switch-
like manner or a single phosphosite being the sole regulator of
protein stability. As previously reported (Han et al., 2009; Tribou-
let et al., 2009), increased DGCR8 protein levels correlated with
the levels of tagged, cotransfected Drosha. Indeed, increased
Drosha protein levels were independent of Drosha mRNA levels
(Figure 3B). Comparable changes in Mut23-DGCR8 versus
Mim23-DGCR8 protein levels were also seen in transfected
HeLa cells (Figure 3A, lanes labeled D [DMSO]), indicating a
general rather than a cell-specific effect.
To confirm that phosphorylation of DGCR8 increases its sta-
bility, we generated two different strains of HeLa cells that stably
express F-DGCR8 constructs (F-DGCR8 Mut23, WT, Mim23, or
the empty vector) from the same chromosomal site within each
strain (Flp-In cells; see the Supplemental Experimental Proce-
dures; WT-F-DGCR8 and the empty vector from strain 1 were
used for Figure 2D above). These two cell lines exhibit levels of
exogenous DGCR8 that are 15- to 45-fold higher than endog-
enous levels, and Drosha protein levels that are 2- to 5-foldhors
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Figure 3. Expression of the Phosphomimetic Increases DGCR8 Stability
(A) Inhibition of phosphatase stabilizes DGCR8 protein. HeLa cells were transiently transfected with vectors expressing GFP, Myc-Drosha, and either WT-FH-
DGCR8, Mut23-FH-DGCR8, or Mim23-FH-DGCR8. After 24 hr, cells were treated with either DMSO (D, control) or calyculin A (Cal) for 20 min before harvesting.
Immunoblotting for Drosha, DGCR8, and GAPDH was performed on total cell lysates.
(B) In transiently transfected HEK 293T cells, increased DGCR8 protein levels are observed as the number of residues available for phosphorylation or mimicking
phosphorylation increases. HEK 293T cells were transiently transfected with vectors expressing GFP, Myc-Drosha, and either an empty vector or WT-FH-
DGCR8, Mut23-FH-DGCR8, Mut14-FH-DGCR8, Mim11-FH-DGCR8, or Mim23-FH-DGCR8. Equal portions of cells were used for immunoblotting and making
RNA preparations for northern blots. Northern blots were probed with antisense oligonucleotides specific for GFP or for the tag sequences for Drosha (Myc) and
DGCR8 (FLAG). Quantitative analyses of protein levels from immunoblots (top) and RNA levels from northern blots (bottom), normalized to Mut23 protein and
mRNA levels, respectively, are shown on the right. Values represent mean ± SEM, n = 5.
(C) Stably transfected HeLa cells also show increased DGCR8 protein levels as the number of residues available for phosphorylation or mimicking of phos-
phorylation increases. Immunoblots showing protein levels in total cell lysates from two isogenic strains of HeLa Flp-In cells stably expressing WT-F-DGCR8,
Mut23-F-DGCR8, Mim23-F-DGCR8, or an empty vector.
(D) Increased DGCR8 protein levels are due to differences in protein stability. Strain 2 isogenic HeLa Flp-In cells stably expressing WT-F-DGCR8, Mut23-F-
DGCR8, or Mim23-F-DGCR8 were treated with 100 mg/ml cycloheximide. Cells were harvested at 0, 2, 4, 8, 12, and 24 hr. Immunoblots were performed on total
cell lysates to monitor DGCR8 decay. Quantitative analyses are shown on the right. Values are normalized to protein levels at 0 hr and represent mean ± SEM,
n = 3. Fitting the curves with single-exponential decays (amplitude fixed at 1 and baseline at 0) generated the following t1/2 values (mean ± SD): Mim23 = 24 ±
1.8 hr, Mut23 = 11 ± 0.77 hr, WT = 12 ± 0.55 hr.
See also Figure S3.higher. Although the protein levels of Mim23 relative to Mut23
are 2- to 3-fold higher in both cell lines (Figure 3C), the level of
WT-DGCR8, which retains the ability to respond to various
signaling cascades, varies between the two cell lines: WT-
F-DGCR8 levels are comparable to those of Mim23 in strain 1
and those of Mut23 in strain 2. This is likely due to variations
in activated signaling cascades in different cell lines and is
consistent with the idea that DGCR8 levels are regulated by
phosphorylation.Cell ReThen, we used these stably expressing HeLa cell lines to
verify that the observed differences in phosphomutant and
phosphomimetic DGCR8 protein levels were due to changes
in protein stability by measuring protein decay after treating
the cells with the translation inhibitor cycloheximide. In strain
2, Mim23-F-DGCR8 had a half-life of 22 hr, whereas WT-F-
DGCR8 and Mut23-F-DGCR8 had half-lives of 11 hr (Fig-
ure 3D). In strain 1, where WT levels were closer to those of
Mim23, decay rates after cycloheximide treatment wereports 5, 1070–1081, November 27, 2013 ª2013 The Authors 1075
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Figure 4. Phosphorylation of DGCR8 Does
Not Alter Its Localization or Ability to Asso-
ciate with Drosha or Itself
(A) Drosha is not differentially coimmunoprecipi-
tated with the DGCR8 phosphosite mutants. HEK
293T cells were transiently transfected with
vectors expressing GFP, Myc-Drosha, and either
an empty vector or WT-FH-DGCR8, Mut23-
FH-DGCR8, Mim23-FH-DGCR8, or WT-SNAP-
DGCR8. Immunoblots of anti-FLAG immunopre-
cipitated MCs were probed for Drosha, DGCR8,
and GAPDH. The anti-DGCR8 panel is reproduced
from Figure 2B.
(B) The stabilization of DGCR8 protein levels is
independent of MC formation. HEK 293T cells
were transiently transfected with GFP and either
an empty vector or vectors expressing WT-FH-
DGCR8, Mut23-FH-DGCR8, Mut14-FH-DGCR8,
Mim11-FH-DGCR8, or Mim23-FH-DGCR8. Equal
portions of cells were used for immunoblotting and
making RNA preparations for northern blots.
Northern blots were probed with oligonucleotides
specific for GFP or the tag sequence in the case of
DGCR8 (FLAG). Quantitative analyses of protein
expression levels from immunoblots and RNA
expression levels from northern blots, normalized
to Mut23 protein and mRNA levels, respectively,
are shown below. Values represent mean ± SEM,
n = 6.
(C) Phosphomutant and phosphomimetic DGCR8
do not show altered cellular localization. Immu-
nofluorescence of isogenic HeLa Flp-In cells stably expressing WT-FLAG-DGCR8, Mut23-FLAG-DGCR8, or Mim23-FLAG-DGCR8. The subnuclear distribution
of all DGCR8 constructs, WT-FLAG-DGCR8, Mut23-FLAG-DGCR8, andMim23-FLAG-DGCR8was variable, sometimes exhibiting foci and sometimes localizing
to nucleoli.
(D) Phosphomutant and phosphomimetic DGCR8s, like WT DGCR8, self-associate. HEK 293T cells were transiently transfected with vectors expressing either
WT-FH-DGCR8, Mut23-FH-DGCR8, or Mim23-FH-DGCR8, and either WT-SNAP-DGCR8, Mut23-SNAP-DGCR8, or Mim23-SNAP-DGCR8, as well as GFP.
DGCR8 was isolated via anti-FLAG immunoprecipitation. SNAP- and FH-tagged versions of DGCR8 can be distinguished by migration shifts.examined over a more limited number of time points, and WT-
F-DGCR8 showed stability similar to that observed for the
Mim23 construct (Figure S3). Together, these data argue that
phosphorylation stabilizes DGCR8 protein, which results in
increased MC levels.
The Increased Stabilization of Phosphomimetic DGCR8
Is Not Due to Altered Localization or Ability to Associate
with Drosha or Itself
Increased DGCR8 protein stability could result primarily from
protein phosphorylation or secondarily from phosphorylation-
induced changes in association with Drosha, ability to self-asso-
ciate, or cellular localization. DGCR8 phosphorylation does not
appear to significantly affect interactions with Drosha. Mim23-
DGCR8, WT- DGCR8, and Mut23-DGCR8 all coimmunoprecipi-
tated cotransfected Drosha protein comparably, with the
amount of associated Drosha being proportional to the amount
of DGCR8 (Figure 4A). Consistent with the fact that none of the
phosphosites are in the segment of DGCR8 required for associ-
ation with Drosha (Yeom et al., 2006), we conclude that the
increased protein stability of phosphorylated DGCR8 is not
due to differential interactions with Drosha. Figure 4A also shows
that DGCR8 can coimmunoprecipitate considerably more Dro-
sha than is present endogenously, suggesting that endogenous1076 Cell Reports 5, 1070–1081, November 27, 2013 ª2013 The AutDrosha levels are not high enough to bind the overexpressed
DGCR8 stoichiometrically. However, Mim23-DGCR8 shows
increased protein levels compared with WT- DGCR8 or Mut23-
DGCR8 when expressed either transiently in HEK 293T cells
(Figure 4B) or stably in strain 1 or 2 HeLa cells (Figure 3C),
even though Drosha is not overexpressed and therefore is not
available to bind DGCR8 stoichiometrically in either cellular
context. Therefore, we further conclude that, unlike Drosha pro-
tein, which is stabilized by complex formation with DGCR8 (Han
et al., 2009), the stabilizing effect of phosphorylation on DGCR8
protein is independent of MC formation.
All 23 DGCR8 phosphosites appear in the N terminus, which is
required for nuclear localization (Yeom et al., 2006) and for the
ability of DGCR8 to homodimerize (Faller et al., 2007). We per-
formed immunofluorescence studies on strain 2 HeLa cells
stably expressing F-DGCR8 constructs. As was observed for
WT-F-DGCR8, both the Mut23 and Mim23 proteins localized
exclusively to the nucleus (Figure 4C). Phosphorylation also did
not significantly alter DGCR8’s ability to self-associate. As
reported previously (Han et al., 2004), WT-FH-DGCR8 coimmu-
noprecipitated a differently tagged WT DGCR8 construct
(SNAP-DGCR8) (Figure 4D). Mut23-FH and Mim23-FH coimmu-
noprecipitated SNAP-taggedMut23 andMim23, respectively, to
the same extent (Figure 4D).hors
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Figure 5. Expression of Phosphomimetic
DGCR8 Leads to a ProgrowthMiRNA Profile
and Increases Cell Proliferation and In Vitro
Scratch Closure Rates
(A) MCs incorporating phosphomutant or phos-
phomimetic DGCR8 do not show altered specific
pri-miRNA processing activity. In vitro pri-miRNA-
processing assays were performed by incu-
bating 32P body-labeled pri-miR16-2 and a
short (35 nt) stable RNA, which functions as a
loading control (LC), with immunoprecipitated
MCs from equal concentrations of lysates from
HEK 293T cells that had been transiently trans-
fected with GFP, Myc-Drosha, and either an
empty vector or vectors expressing WT-FH-
DGCR8, Mut23-FH-DGCR8, Mut14-FH-DGCR8,
Mim11-FH-DGCR8, or Mim23-FH-DGCR8. The
input RNAs are shown in the far-right lane.
Contrast has been adjusted separately on the
ladder lane. Ladder sizes are indicated on the right
in nucleotides.
(B) Cells expressing phosphomimetic DGCR8,
compared with WT or phosphomutant DGCR8,
show a progrowth miRNA profile. Next-generation
sequencing was used to profile levels of small
RNAs from strain 2 isogenic HeLa Flp-In
cells stably expressing Mim23-F-DGCR8, WT-F-
DGCR8, or Mut23-F-DGCR8. Each dot represents
(for an individual maturemiRNA) the average (n = 3)
log2 relative expression in Mim23-F-DGCR8 over
Mut23-F-DGCR8 cells versus the log2 relative
expression in Mim23-F-DGCR8 over WT-F-
DGCR8 cells. Dotted lines are shown at 1 and 1,
corresponding to a 2-fold change up or down,
respectively. Thus, a miRNA with a >2-fold up or down change in the Mim23 sample relative to both the Mut23 and WT sample will be in the upper-right or
lower-left quadrant. Error bars are omitted for simplicity.
(C) Cells expressing phosphomimetic DGCR8, compared with WT or phosphomutant DGCR8, show a faster in vitro scratch closure rate. Strain 2 isogenic HeLa
Flp-In cells stably expressing WT-F-DGCR8, Mut23-F-DGCR8, or Mim23-F-DGCR8 were plated at 500,000 cells per 10 cm plate. After settling overnight, cells
were serum starved 24 hr. Then, a 200 ml pipette was used to create a scratch before readdition of serum. Cells were photographed every 12 hr.
(D) Cells expressing phosphomimetic DGCR8, compared with WT or phosphomutant DGCR8, show increased cell proliferation rates. Strain 2 isogenic HeLa
Flp-In cells stably expressing WT-F-DGCR8, Mut23-F-DGCR8, or Mim23-F-DGCR8 were plated at 200 cells per well in a 96-well plate. After settling overnight,
cells were serum starved 24 hr. Upon serum addition, cell proliferation was measured every 24 hr for 5 days using Cell Titer Glo reagent. Plots of luminescence
normalized to average luminescence on day 1 (mean ± SEM, n = 6) versus time were fit to a single-exponential growth equation (value at time 0 fixed at 1), which
determined the doubling rates (t) of (mean ± SD).
See also Figures S4 and S5 and Tables S4–S6.MCs Containing Phosphomutant or Phosphomimetic
DGCR8 Are Not Altered in Specific Processing Activity
To test whether Drosha’s catalytic activity is altered by associa-
tion with phosphorylated DGCR8, we incubated equal volumes
of immunoprecipitated MCs from transiently transfected
HEK 293T cell cultures with body-labeled, in vitro-transcribed
pri-miRNA substrates. Processing activity, as measured by the
yield of pre-miRNA relative to the loading control, correlated
with MC expression levels in these cells, i.e., it was lower than
in theWT forMCs containingMut23, and higher forMCs contain-
ing Mim23 (Figures 5A and S4A). Note that these reactions con-
tained different amounts of MC, since DGCR8 concentrations in
immunoprecipitates are proportional to lysate concentrations
(Figure S4B).
This in vitro assay detects primarily the activity of MCs that
are minimally composed of Drosha and DGCR8, since (1)
interacting proteins were not cotransfected and thereforeCell Rewere not present in quantities stoichiometric to Drosha
and DGCR8, and (2) the immunoprecipitates were washed
with high salt concentrations (250 mM) to minimize the
copurification of other factors. Nonetheless, the immuno-
precipitated MCs were probed for two of the best-known
MC-interacting factors (the p68 and p72 helicases; Fig-
ure S4C), other factors known to regulate pri-miRNA cleavage
(KHSRP, SRp20, RNH1, Ars2, and FUS), and the downstream
miRNA biogenesis factor Exportin 5 (data not shown).
Although all were present at higher levels in the immunopre-
cipitates than in the nonspecific controls, their levels in each
immunoprecipitate were proportional to the amount of
DGCR8, indicating that there were no significant differences
in cofactor association. These results argue that DGCR8 phos-
phorylation does not significantly alter the specific processing
activity of individual minimal MCs into which DGCR8 is
incorporated.ports 5, 1070–1081, November 27, 2013 ª2013 The Authors 1077
Expression of Phosphomimetic DGCR8 Generates a
Progrowth miRNA Expression Profile and Increases
Cell Proliferation
Since the specific activities of individual MCs were not signifi-
cantly affected by the incorporation of Mut23 or Mim23
DGCR8, we tested whether the differences in protein levels
observed when these DGCR8 mutants were stably expressed
led to differences in miRNA biogenesis. We used next-genera-
tion sequencing to profile small RNAs from strain 2 HeLa cells
stably expressing Mim23-DGCR8, Mut23-DGCR8, or WT-F-
DGCR8 (Figure 5B). It should be noted that although DGCR8 is
overexpressed in these cells, its level was observed by immuno-
fluorescence to be uniform from cell to cell due to stable
transformation. Moreover, it has been reported that highMCper-
formance can be achieved even when MC levels significantly
exceed cellular levels of pri-miRNAs (Barad et al., 2012). We
normalized individual miRNA read counts by the total number
of miRNA reads per sample and then averaged the log2-fold
changes over the three biological replicates (Figures S5A and
S5B). This strategy yielded average fold changes for mature
miRNAs that were consistent with values obtained by TaqMan
quantitative PCR (Figure S5C). The average log2-fold change
for cells expressing the mimetic versus the mutant DGCR8
was 0.38 ± 0.035 (corresponding to a fold change of 1.28–
1.34), whereas the average log2-fold change for the mimetic
over the WT was 0.32 ± 0.031 (corresponding to a fold change
of 1.22–1.27). The 2- to 3-fold differences in cellular protein levels
for the DGCR8 WT and mutants would be expected to alter
global levels of mature miRNAs if DGCR8 were limiting for
miRNA biogenesis. However, given the complexity in normaliza-
tion of RNA sequencing values (Dillies et al., 2012; Robinson and
Oshlack, 2010), we do not believe the small increase in global
miRNA abundance is significant. This conclusion is consistent
with previouswork showing that other components of themiRNA
biogenesis pathway are limiting (Diederichs and Haber, 2007; Yi
et al., 2005) and with models of DGCR8 haploinsufficiency that
show effects only on selected miRNAs (Schofield et al., 2011;
Stark et al., 2008).
Because miRNA biogenesis is highly regulated, certain
miRNAs appeared to be more sensitive to MC levels and/or
the phosphorylation status of DGCR8. Of 616 miRNAs, 75
showed a >2-fold increase in the Mim23 cell line relative to
both theWT- andMut23-expressing cell lines (upper-right quad-
rant of Figure 5B; Tables S4–S6). Of the 75 upregulated miRNAs,
the most abundant (those with the highest total read count) were
miR-10a-5p and miR-10b-5p. Only seven miRNAs showed
a >2-fold decrease in the Mim23 cell line (lower-left quadrant
of Figure 5B; Table S5). Of those seven, the most abundant
was miR-129-5p. The miR-10 family of miRNAs is deregulated
in several types of cancer (Lund, 2010). MiR-10b is highly
expressed in metastatic breast cancer cells, where it positively
regulates cell migration and invasion (Ma et al., 2007), and the
level of miR-10a affects the capacity of cells to undergo onco-
genic transformation (Ørom et al., 2008). MiR129-5p, on the
other hand, has been reported to have an antiproliferative effect
by targeting Cdk6 (Wu et al., 2010). Neither miR-10b nor
miR-129-1 was processed with significantly different efficiency
by MCs containing DGCR8 mutants (Figure S4A). Therefore,1078 Cell Reports 5, 1070–1081, November 27, 2013 ª2013 The Autthe in vivo sensitivity of mature miR-10b and miR-129 levels to
DGCR8 protein level or phosphorylation status could be due to
differential interactions with some protein cofactor that regulates
processing or to indirect effects of DGCR8 phosphorylation.
The upregulation of the tumorigenic, progrowth miR10a and
miR10b, and downregulation of the antiproliferative miR129-5p
seen in the Mim23-expressing cells would be predicted to alter
cell growth and invasion properties. Indeed, in an in vitro scratch
assay, Mim23-expressing cells exhibited faster rates of scratch
closure compared with Mut23- and WT-expressing cells
(Figure 5C). HeLa cells expressing Mim23-F-DGCR8 showed
higher doubling rates than those expressing Mut23-DGCR8 or
WT-F-DGCR8 (Figure 5D). The increased proliferation rate of
Mim23-expressing cells, which show higher MC levels than
WT-DGCR8-expressing cells, is consistent with reports that
DGCR8 knockout (Chapnik et al., 2012; Chen et al., 2012; Steiner
et al., 2011; Wang et al., 2007; Yi et al., 2009) or sequestration
(Sellier et al., 2013) leads to cell-cycle defects or apoptosis.
Thus, the phosphorylation of DGCR8 may be a means by
which the MC senses cell-cycle regulation cues, leading to cell
proliferation.
DISCUSSION
We have investigated the impact of protein modification on the
critical miRNA biogenesis factor DGCR8. Our results demon-
strate that multisite phosphorylation regulates DGCR8 protein
stability, thereby raising MC levels (Figure 3), changing the
mature miRNA profile of the cell, and increasing cell proliferation
and migration (Figure 5). Moreover, we find that the accumula-
tion of multiple phosphorylations creates a graded response in
DGCR8 stability (Figure 3B), rather than a single phosphosite
modulating DGCR8 protein. The modifications are introduced
at least in part by ERK/MAPKs in vivo (Figure 2), linking control
of miRNA biogenesis to extracellular cues. Because miRNAs
have been implicated in a myriad of biological functions and
disease processes, it is not surprising that their biogenesis is
regulated at many levels. Our findings provide important mech-
anistic insights into the functional and biological consequences
of DGCR8 phosphorylation.
Previously, multisite phosphorylation of proteins was found to
regulate protein function in either a graded fashion, as we have
found, or by a switch-like response (Nash et al., 2001; Serber
and Ferrell, 2007; Strickfaden et al., 2007). The levels of
DGCR8 are tightly regulated by two autoregulatory feedback
mechanisms: one in which the microprocessor cleaves Dgcr8
mRNA (Han et al., 2009; Kadener et al., 2009; Triboulet et al.,
2009) and one in which the levels of DGCR8 adjust to those of
pri-miRNA substrates (Barad et al., 2012). Multisite phosphoryla-
tion represents yet another possible mechanism to ensure tight
control over microprocessor levels to keep them in an optimal
range for activity.
Modulation of protein stability by phosphorylation is becoming
a common theme in biology, and examples of crosstalk between
phosphorylation and ubiquitin-mediated degradation of proteins
are increasingly being reported (Hunter, 2007). Within themiRNA
biogenesis pathway itself, changes in the PTMs of miRNA pro-
cessing enzymes and their dsRNA-binding partners, effectedhors
by cell-signaling pathways, have been reported for TRBP2 and
Drosha phosphorylation, and for DGCR8 and Drosha acetylation
(Paroo et al., 2009; Tang et al., 2010, 2011, 2013; Wada et al.,
2012). Exactly how phosphorylation confers increased stability
to DGCR8 or TRBP2 is not yet known. The mapped DGCR8
phosphosites all exist within regions that are known to be impor-
tant for nuclear localization or homodimerization, yet neither of
these properties of DGCR8 was affected by DGCR8 phosphory-
lation (Figures 4C and 4D). Drosha protein levels also did not
appear to be important for stabilization of phosphomimetic-
DGCR8 (Figure 4B). It has been suggested that DGCR8 might
exist in complexes with endonucleases and proteins other than
Drosha (Macias et al., 2012; Shiohama et al., 2007). The different
interacting partners of phosphorylated and unphosphorylated
DGCR8warrant future studies to determine whether an unknown
protein binding partner interacts preferentially with one form or
another. Such studies could also identify other kinases acting
on DGCR8, and could elucidate whether DGCR8 is a target of
ubiquitin-mediated degradation by identifying a ubiquitin
E3-ligase that preferentially binds the unphosphorylated form,
leading to DGCR8 ubiquitination and degradation. DGCR8
shows several RXXL motifs (i.e., potential APC/C-recognized
destruction boxes).
DGCR8 was recently shown to be the target of caspase
3-mediated cleavage (Gong et al., 2012). Significant crosstalk
between phosphorylation and caspase cleavage has been docu-
mented (Dix et al., 2012) and phosphorylation of DGCR8 at S397
(the amino acid immediately C-terminal to the caspase-cleaved
scissile bond) is predicted to interfere with caspase cleavage
(To¨zse´r et al., 2003). However, the observed differences in pro-
tein stability among our WT-DGCR8, Mim23-DGCR8, and
Mut23-DGCR8 constructs cannot be explained solely by differ-
ences in susceptibility to caspase-mediated cleavage, as we
observed little, if any, caspase 3 activity (determined by blotting
for cleaved Poly ADP ribose polymerase) in either our transiently
transfected or stable cell lines (data not shown). Additionally,
after incubating immunoprecipitated WT-FH-DGCR8, Mut23-
FH-DGCR8, or Mim23-FH-DGCR8 from HEK 293T cells with re-
combinant caspase 3 or activating caspases in the various
DGCR8-expressing cells with etoposide, we observed similar
extents of DGCR8 cleavage by caspase for all three constructs
(data not shown). These observations preliminarily indicate that
phosphorylation does not regulate caspase cleavage of DGCR8.
We have demonstrated that phosphorylation driven by ERK/
MAPKs regulates MC levels. ERKs are mitogenic kinases that
drive cellular proliferation upon signaling stimulation mainly by
extracellular growth factors. Accordingly, HeLa cells stably ex-
pressing Mim23-F-DGCR8 showed increased cell proliferation
and invasion relative to Mut23-F-DGCR8 and WT-F-DGCR8-
expressing cells, and the progrowth miR-10a and miR-10b
were significantly enhanced (Figure 5). The phosphorylation of
DGCR8 by ERK1 and ERK2 during the cell cycle and/or upon
extracellular stimulation may thus be one way in which the MC
senses regulatory cues to promote cell proliferation. This finding
is similar to observations regarding TRBP2 phosphorylation by
ERKs (Chakravarthy et al., 2010; Paroo et al., 2009). Since
DGCR8 and TRBP2 respond comparably to ERK/MAPKs, we
investigated whether expression of phosphomimetic or phos-Cell Rephomutant DGCR8 might affect TRBP2 protein levels, but we
found no evidence for such a feedback loop between the nuclear
and cytoplasmic arms of the miRNA biogenesis pathway (data
not shown). However, it will be important to further characterize
the signaling pathways that target the MC and miRNA biogen-
esis in general, given that many drugs inhibit kinases and thus
have the potential to reprogram miRNA expression.
DGCR8 is an integral component of the cellular micropro-
cessor. The phosphorylation events we have identified allow
the cell to respond to extracellular cues, such as the mitogens
that stimulate ERK1 and ERK2, and appear comparable to the
digital data input that a computer microprocessor receives.
Changes in DGCR8 stability induced by phosphorylation events
likewise result in an altered digital output that affects cellular
growth rates.
EXPERIMENTAL PROCEDURES
Plasmids
pFLAG/HA-DGCR8 (pFH-DGCR8) and pcDNA4/TO/cmycDrosha (Landthaler
et al., 2004) were purchased from Addgene. Details on how pCS3-MT-
MycDrosha; all WT, mutant, and mimetic FH-DGCR8 constructs (for transient
transfections); pSNAP-DGCR8 (for transient transfections); pcDNA5/FRT-
F-DGCR8 (for stable transfections); pET28a-DGCR8 (for bacterial expression);
and pFast-Bac1-HisDGCR8 (for baculovirus expression) were cloned from the
original pFH-DGCR8 and pcDNA4/TO/cmycDrosha plasmids are provided in
the Supplemental Experimental Procedures. The sequences of each mutant
and mimetic construct are given in Table S2. pGFPmax was used for two
reasons: (1) it allowed determination of transfection efficiency and (2) it
provided a loading control for the northern blots. pcDNA3 was used as the
empty vector control.
Mammalian Cell Assays
Details on cell culture, transfections, cell lysis, metabolic labeling, develop-
ment of stable cell lines, and proliferation assays are provided in the Supple-
mental Experimental Procedures.
Immunoprecipitations, Blots, Immunofluorescence, and In Vitro
Processing Assays
Immunoprecipitations and immunoblots were performed according to
Pimienta et al. (2007) and Pimienta et al. (2011), respectively. Immunofluores-
cence, northern blots, and in vitro processing assays were performed accord-
ing to Pawlicki and Steitz (2008). Detailed protocols with modifications are
provided in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, one data file, and six tables and can be foundwith this article online
at http://dx.doi.org/10.1016/j.celrep.2013.10.017.
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